CurrentBlue Cross Blue Shield - OklahomaPolicy CPCPLAB044

Lyme Disease Testing

This policy defines Blue Cross Blue Shield of Oklahoma's reimbursement and coverage criteria for laboratory testing related to diagnosis of Lyme disease, and applies to providers submitting claims for members covered under BCBSOK plans.

Policy Summary

PayerBlue Cross Blue Shield - Oklahoma

PolicyLyme Disease Testing

Policy CodePolicy CPCPLAB044

Change TypeAdded code

Effective DateAug 1, 2025

Next Review Date

Key ActionVerify product-specific coverage and prior authorization requirements with plan documents before ordering Lyme disease testing.

SourceLink

POLICY UPDATE CHANGES

Added code 0580U effective 10/01/2025.

8listed procedure/test codes

2-tierpreferred serologic testing strategy

14 daysPCR may replace serology for neurologic symptoms <14d

0testing of tick reimbursable

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Primary criteria: Individual has symptoms of Lyme disease AND history of travel to or residence in a Lyme-endemic region (with or without known tick bite)

Serologic testing should follow a 2-tier strategy (sensitive EIA/IFA followed by Western blot or FDA-cleared second EIA)

Alternate clinical presentations: For individuals with history of travel to an endemic region, serologic testing may be reimbursable for: (a) acute myocarditis/pericarditis of unknown cause; (b) meningitis, encephalitis, or myelitis; (c) painful radiculoneuritis; (d) mononeuropathy multiplex (including confluent); (e) acute cranial neuropathy.

These presentations may qualify even if classic erythema migrans rash is absent

Not reimbursable — serology

Serologic testing is not reimbursable in any of the following situations

Explicit non-reimbursable conditions: (a) Erythema migrans (EM) rash — manage clinically; (b) screening asymptomatic patients living in endemic areas; (c) non-specific symptoms only (e.g., fatigue, myalgias/arthralgias); (d) amyotrophic lateral sclerosis; (e) relapsing-remitting multiple sclerosis; (f) Parkinson's disease; (g) dementia or cognitive decline or new-onset seizures; (h) psychiatric illness.

Claims for these indications are not reimbursable

PCR, repeat testing, and excluded tests

PCR in CSF: PCR-based direct detection of B. burgdorferi in cerebrospinal fluid (CSF) may be reimbursable and may replace serologic documentation for patients with short-duration neurologic symptoms<14 days

Use within the window before detectable antibodies are present

Repeat testing: Repeat serologic testing in individuals who previously tested positive for Lyme disease is not reimbursable

Repeat testing after prior positive is not covered

Excluded tests: All other testing for Borrelia burgdorferi not described as reimbursable is not reimbursable; testing of the individual tick for diagnosis is not reimbursable

Serologic testing is not reimbursable in several specific clinical contexts: presence of an erythema migrans (EM) rash (patients with EM who live in or recently traveled to an endemic area should be treated clinically), screening of asymptomatic patients in endemic areas, or evaluation for non‑specific symptoms only (for example, fatigue, myalgias/arthralgias). Additionally, serologic testing is not reimbursable for certain listed neurologic, degenerative, or psychiatric diagnoses including amyotrophic lateral sclerosis, relapsing‑remitting multiple sclerosis, Parkinson’s disease, dementia or cognitive decline or new‑onset seizures, or for individuals with psychiatric illness.

Covered Indications

Diagnosis of suspected Lyme disease in symptomatic individuals with travel/residence in endemic areas; specified neurologic or cardiac presentations; PCR of CSF for early neurologic disease <14 days

Covered clinical diagnosis: Diagnosis of suspected Lyme disease in symptomatic individuals with travel or residence in an endemic area; serologic testing must follow a 2-tier strategy (sensitive EIA/IFA followed by Western blot or FDA-cleared second EIA)

See alternate clinical presentations that qualify even without classic EM rash

Specified neurologic or cardiac presentations: Serologic testing may be reimbursable for acute myocarditis/pericarditis of unknown cause; meningitis, encephalitis, or myelitis; painful radiculoneuritis; mononeuropathy multiplex (including confluent); or acute cranial neuropathy.

These presentations apply for individuals with travel/residence in endemic areas

PCR for early neurologic disease: Polymerase chain reaction (PCR)-based direct detection of B. burgdorferi in CSF may be reimbursable and may replace serologic testing for patients with short-duration neurologic symptoms within 14 days of symptom onset<14 days

Use PCR during the antibody window between exposure and production of detectable antibodies

Provider Actions and Billing Guidance

Prior Authorization

Prior Authorization / Product Coverage

Verify product-specific coverage and prior authorization requirements before ordering Lyme disease testing. Not all lab management reimbursement criteria apply to every BCBSOK product; providers should confirm the member’s plan benefits, prior authorization rules, and any product-specific limitations with the payer or via the provider portal.

Check the member's plan documents (Certificate of Benefits, summary plan description) for coverage specifics and benefit limits.
Obtain prior authorization when required by the member's product or contract.
Retain and submit supporting documentation upon request to substantiate medical necessity.

Documentation Required

Clinical Documentation to Support Testing

For serologic testing to be reimbursable, clinical documentation must clearly support medical necessity. Include symptom details, travel or residence in an endemic area, relevant exposure history, and the clinical indication that matches covered scenarios.

Document presence of signs or symptoms consistent with Lyme disease and travel/residence in an endemic region, or one of the specific clinical syndromes listed (e.g., acute myocarditis/pericarditis of unknown cause, meningitis, encephalitis, myelitis, painful radiculoneuritis, mononeuropathy multiplex, acute cranial neuropathy).
If ordering PCR on CSF for acute neurologic symptoms <14 days, document symptom onset date and rationale for direct detection instead of serology.
For previously positive patients, document rationale — repeat serologic testing is not reimbursable.

Note

Preferred Testing Sequence

Follow a 2-tier testing strategy when serologic testing is appropriate: begin with a sensitive enzyme immunoassay (EIA) or immunofluorescence assay (IFA), followed by a Western immunoblot or an FDA-cleared second EIA for confirmation. PCR testing of CSF may be used in patients with short-duration neurologic symptoms (<14 days) and can replace serologic testing in that window.

Order an initial sensitive EIA or IFA; only perform the confirmatory test (Western blot or FDA-cleared second EIA) when the initial screen is reactive as part of the 2-tier approach.
Do not rely on serology alone for patients with erythema migrans; treat clinically instead of ordering serologic testing for classic EM.
Consider PCR on CSF for acute neurologic presentations <14 days to detect B. burgdorferi directly.

Ordering Requirements

Note

Ordering requirements — confirm authority, coverage, and documentation

Ensure tests are ordered by appropriate providers per plan/provider contract, confirm product coverage/prior authorization, and include clinical documentation supporting the indication and exposure when ordering.

Confirm who may order tests according to the member's plan documents and provider contract.
Verify product‑specific coverage and any prior authorization requirements before ordering.
Attach clinical notes documenting symptoms and travel/residence in an endemic area or the specific clinical presentation that justifies testing.

Frequency Limits

Serology frequency limit — repeat serologic testing after prior positive test

Frequency limitRepeat serologic testing in individuals with a prior positive test is not reimbursable (lifetime/indefinite).

ScopeApplies to serologic testing for Lyme disease (two-tier serology).

Exception noteRepeat testing after prior positive is explicitly listed as not reimbursable and may result in claim denial.

Not Covered

The following serologic testing indications are not covered/not reimbursable: testing when an erythema migrans (EM) rash is present; asymptomatic screening of persons in endemic areas; evaluation for non‑specific symptoms only (e.g., fatigue, myalgias/arthralgias); testing for listed neurologic or degenerative conditions such as amyotrophic lateral sclerosis, relapsing‑remitting multiple sclerosis, Parkinson’s disease, and for dementia/cognitive decline or new‑onset seizures; testing for psychiatric illness. Repeat serologic testing after a prior positive test and testing of the tick are also not reimbursable, and other Borrelia tests not described as reimbursable are excluded.

Definitions

Two-tier testing strategy definition — EIA/IFA then western blot or FDA-cleared second EIA

DefinitionTwo-tier testing strategy: initial sensitive enzyme immunoassay (EIA) or immunofluorescence assay (IFA), followed by a western immunoblot assay or an FDA-cleared second EIA.

Intended useRequired reimbursable approach for serologic diagnosis of Lyme disease in symptomatic individuals with relevant exposure history.

Related guidanceProviders should follow this sequence for serologic testing to meet reimbursement criteria.

PCR-based direct detection definition — PCR of B. burgdorferi in CSF for short-duration neurologic symptoms (<14 days)

DefinitionPCR-based direct detection: polymerase chain reaction (PCR) testing for Borrelia burgdorferi in cerebrospinal fluid (CSF).

Clinical windowMay be reimbursable and may replace serologic documentation for patients with short-duration neurologic symptoms (<14 days).

RationaleUse during the window between exposure and production of detectable antibodies when serology may be negative.

Background

Diagnosis of Lyme disease relies primarily on clinical presentation and targeted laboratory testing. For serologic diagnosis, a 2‑tier testing strategy (a sensitive enzyme immunoassay/immunofluorescence assay followed by a Western immunoblot or an FDA‑cleared second EIA) is the standard reimbursable approach. Polymerase chain reaction (PCR)‑based direct detection of B. burgdorferi in cerebrospinal fluid may be reimbursable and can replace serology for patients with short‑duration neurologic symptoms occurring within the antibody window (14 days). Many specialized or repeat tests and testing of ticks are explicitly not reimbursable.